SuperworthPasithea Therapeutics KTTA
- Market cap
- $13.5M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Pasithea Therapeutics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $1.6M+27% | $3.4M+142% | $1.7M+60% | $2.4M+16% | $1.6M−3% | $1.5M−55% | $1.7M−1% | $2.1M−9% | $1.4M−14% | $2.7M+82% | $2.9M+70% | $3.7M+72% |
| SG&A | $2.2M−16% | $1.8M−32% | $2.3M+8% | $1.6M−12% | $1.4M−34% | $1.7M−3% | $2M−15% | $1.7M+5% | $1.8M+23% | $7.5M+329% | $1.9M−1% | $2M+22% |
| −$3.8M−2% | −$5.1M+27% | −$4M+26% | −$3.9M+3% | −$3M−21% | −$3.3M−37% | −$3.7M−9% | −$3.8M−3% | −$3.1M+4% | −$10.3M+215% | −$4.9M+33% | −$5.7M+50% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$3.6M−14% | −$5M+24% | −$3.9M+18% | −$3.9M+8% | −$3M−17% | −$3.2M−37% | −$3.6M−8% | −$3.7M−4% | −$3M+1% | −$10.1M+218% | −$2.9M−20% | −$5.3M+42% |
| Net income | −$3.6M−21% | −$5M−1% | −$3.9M+9% | −$3.9M+3% | −$3M−17% | −$3.2M−37% | −$3.6M−8% | −$3.7M−4% | −$3M+1% | −$10.1M+218% | −$2.9M−20% | −$5.3M+42% |
| −$2.87−16% | −$4.85+35% | −$3.70+37% | −$3.71+29% | −$2.87+0% | −$2.54−48% | −$1.61−57% | −$0.66−82% | −$0.41−86% | −$0.80−69% | −$0.12−93% | −$0.16−76% | |
| 1.3M−5% | 1M−25% | 1M−20% | 1M−20% | 1M−17% | 1.3M+20% | 2.2M+112% | 5.6M+441% | 7.4M+613% | 12.7M+914% | 24.3M+1001% | 32.1M+469% |
EPS, diluted: 14 periods, Q1 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY21: share-days: the 6-month average less the second quarter's. Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY22 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Pasithea Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| KTTAPasithea Therapeutics | $13.5M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Pasithea Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .